Factor VIII/factor IX prophylaxis for severe hemophilia

Seminars in Hematology

Volumn 53, Issue 1, 2016, Pages 3-9

  Carcao, Manuel ^a   Srivastava, Alok ^b  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^b CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

Hemophilia; Individualization; Prophylaxis; Tailoring

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 CONCENTRATE; BLOOD CLOTTING FACTOR CONCENTRATE;

ARTERIOVENOUS SHUNT; BLEEDING; BRAIN HEMORRHAGE; CENTRAL VENOUS CATHETER; DRUG CLEARANCE; DRUG COST; DRUG DOSE ESCALATION; DRUG HALF LIFE; HEALTH CARE ACCESS; HEMARTHROSIS; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; JOINT DESTRUCTION; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PERSONALIZED MEDICINE; PHYSICAL ACTIVITY; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; VEIN PUNCTURE; ECONOMICS; HEMORRHAGE; OUTCOME ASSESSMENT; PHENOTYPE;

FACTOR IX; FACTOR VIII; HEMOPHILIA A; HEMORRHAGE; HUMANS; MEDICATION ADHERENCE; OUTCOME ASSESSMENT (HEALTH CARE); PHENOTYPE;

EID: 84957536370     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2015.10.006     Document Type: Review

References (62)

1. Aledort L.M., Haschmeyer R.H., Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994, 236(4):391-399.
2. Fischer K., van Hout B.A., van der Bom J.G., Grobbee D.E., van den Berg H.M. Association between joint bleeds and Pettersson scores in severe haemophilia. Acta Radiol 2002, 43(5):528-532.
3. Srivastava A., Brewer A.K., Mauser-Bunschoten E.P., et al. Guidelines for the management of hemophilia. Haemophilia 2013, 19(1):e1-47.
4. Manco-Johnson M.J., Abshire T.C., Shapiro A.D., et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007, 357(6):535-544.
5. Gringeri A., Lundin B., von Mackensen S., Mantovani L., Mannucci P.M. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011, 9(4):700-710.
6. Valentino L.A., Mamonov V., Hellmann A., et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost 2012, 10(3):359-367.
7. Manco-Johnson M.J., Kempton C.L., Reding M.T., et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). J Thromb Haemost 2013, 11(6):1119-1127.
8. Blanchette V.S., Key N.S., Ljung L.R., et al. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2014, 12(11):1935-1939.
9. Nilsson I.M., Berntorp E., Lofqvist T., Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992, 232(1):25-32.
10. Schimpf K., Fischer B., Rothmann P. Hemophilia A prophylaxis with factor VIII concentrate in a home-treatment program: a controlled study. Scand J Haematol Suppl 1977, 30:79-80.
11. Liesner R.J., Khair K., Hann I.M. The impact of prophyactic treatment on children with severe haemophilia. Br J Haematol 1996, 92(4):973-978.
12. Smith P.S., Teutsch S.M., Shaffer P.A., Rolka H., Evatt B. Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis. J Pediatr 1996, 129(3):424-431.
13. Traivaree C., Blanchette V., Armstrong D., Floros G., Stain A.M., Carcao M.D. Intracranial bleeding in haemophilia beyond the neonatal period- the role of CT imaging in suspected intracranial bleeding. Haemophilia 2007, 13(5):552-559.
14. Witmer C., Presley R., Kulkarni R., Michael Soucie J., Manno C.S., Raffini L. Associations between intracranial haemorrhage and prescribed prophylaxis in a large cohort of haemophilia patients in the United States. Br J Haematol 2011, 152(2):211-216.
15. Shapiro A.D., Donfield S.M., Lynn H.S., et al. Defining the Impact of Hemophilia: The Academic Achievement in Children With Hemophilia Study. Pediatrics 2001, 108(6):e105.
16. Szucs T.D., ÖFfner A., Kroner B., et al. Resource utilisation in haemophiliacs treated in Europe: Results from the European Study on Socioeconomic Aspects of Haemophilia Care. Haemophilia 1998, 4(4):498-501.
17. Blanchette V.S., McCready M., Achonu C., Abdolell M., Rivard G., Manco-Johnson M.J. A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres. Haemophilia 2003, 9(Suppl 1):19-26.
18. Ljung R., Aronis-Vournas S., Kurnik-Auberger K., et al. Treatment of children with haemophilia in Europe: a survey of 20 centres in 16 countries. Haemophilia 2000, 6(6):619-624.
19. Komvilaisak P., Connolly B., Naqvi A., Blanchette V. Overview of the use of implantable venous access devices in the management of children with inherited bleeding disorders. Haemophilia 2006, 12:87-93.
20. Feldman B.M., Pai M., Rivard G.E., et al. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006, 4(6):1228-1236.
21. Nijdam A., Kurnik K., Liesner R., et al. How to achieve full prophylaxis in young boys with severe haemophilia A: different regimens and their effect on early bleeding and venous access. Haemophilia 2015, 21(4):444-450.
22. Miners A.H., Sabin C.A., Tolley K.H., Lee C.A. Primary prophylaxis for individuals with severe haemophilia: how many hospital visits could treatment prevent?. J Intern Med 2000, 247(4):493-499.
23. Collins P.W., Blanchette V.S., Fischer K., et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 2009, 7(3):413-420.
24. Fischer K., Steen Carlsson K., Petrini P., et al. Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. Blood 2013, 122(7):1129-1136.
25. Daliri A.A., Haghparast H., Mamikhani J. Cost-effectiveness of prophylaxis against on-demand treatment in boys with severe hemophilia A in Iran. Int J Technol Assess Health Care 2009, 25(4):584-587.
26. Wu R., Luke K.H., Poon M.C., et al. Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China. Haemophilia 2011, 17(1):70-74.
27. Gouider E., Rauchensteiner S., Andreeva T., et al. Real-life evidence in evaluating effectiveness of treatment in haemophilia A with a recombinant FVIII concentrate: a non-interventional study in emerging countries. Haemophilia 2015, 21(3):e167-e175.
28. Collins P.W. Personalized prophylaxis. Haemophilia 2012, 18(Suppl 4):131-135.
29. van Dijk K., van der Bom J., Lenting P., et al. Factor VIII half-life and clinical phenotype of severe hemophilia A. Haematologica 2005, 90(4):494-498.
30. Bjorkman S. Population pharmacokinetics of recombinant factor IX: implications for dose tailoring. Haemophilia 2013, 19(5):753-757.
31. Bjorkman S. Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A. Haemophilia 2010, 16(4):597-605.
32. Carlsson M., Berntorp E., Bjorkman S., Lindvall K. Pharmacokinetic dosing in prophylactic treatment of hemophilia A. Eur J Haematol 1993, 51(4):247-252.
33. Bjorkman S., Folkesson A., Jonsson S. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A. Eur J Clin Pharmacol 2009, 65(10):989-998.
34. Ljung R., Auerswald G., Benson G., et al. Novel coagulation factor concentrates: Issues relating to their clinical implementation and pharmacokinetic assessment for optimal prophylaxis in haemophilia patients. Haemophilia 2013, 19(4):481-486.
35. Pollmann H., Richter H., Ringkamp H., Jurgens H. When are children diagnosed as having severe haemophilia and when do they start to bleed? A 10-year single-centre PUP study. Eur J Pediatr 1999, 158(Suppl 3):S166-S170.
36. Carcao M.D., van den Berg H.M., Ljung R., et al. Correlation between phenotype and genotype in a large unselected cohort of children with severe hemophilia Blood 2013, 121(19):3946-3952.
37. Hang M.X., Blanchette V.S., Pullenayegum E., et al. Age at first joint bleed and bleeding severity in boys with severe hemophilia A: Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2011, 9(5):1067-1069.
38. Dijk Kv, van der Bom JG, Fischer K., Grobbee D.E., Marijke van den Berg H. Do prothrombotic factors influence clinical phenotype of severe haemophilia? A review of the literature. Thromb Haemost 2004, 92(8):305-310.
39. Van Dijk K., Van Der Bom J.G., Fischer K., De Groot P.G., Van Den Berg H.M. Phenotype of severe hemophilia A and plasma levels of risk factors for thrombosis. J Thromb Haemost 2007, 5(5):1062-1064.
40. Ghosh K., Shankarkumar U., Shetty S., Mohanty D. Chronic synovitis and HLA B27 in patients with severe haemophilia. Lancet 2003, 361(9361):933-934.
41. van Vulpen L.F.D., Schutgens R.E.G., Coeleveld K., et al. IL-1β, in contrast to TNFα, is pivotal in blood-induced cartilage damage and as such a potential target for therapy Blood 2015, 126(19):2239-2246.
42. Haxaire C., Blobel C.P. With blood in the joint-what happens next? Could activation of a pro-inflammatory signalling axis leading to iRhom2/TNFα-convertase-dependent release of TNFα contribute to haemophilic arthropathy?. Haemophilia 2014, 20:11-14.
43. Risebrough N., Oh P., Blanchette V., Curtin J., Hitzler J., Feldman B.M. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A. Haemophilia 2008, 14(4):743-752.
44. Astermark J., Petrini P., Tengborn L., Schulman S., Ljung R., Berntorp E. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999, 105(4):1109-1113.
45. Fischer K., van der Bom J.G., Mauser-Bunschoten E.P., Roosendaal G., Prejs R., de Kleijn P., Grobbee D.E., van den Berg M. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood 2002, 99(7):2337-2341.
46. Kreuz W., Escuriola-Ettingshausen C., Funk M., Schmidt H., Kornhuber B. When should prophylactic treatment in patients with haemophilia A and B start?-The German experience. Haemophilia 1998, 4(4):413-417.
47. Gouw S.C., van der Bom J.G., Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007, 109(11):4648-4654.
48. Gouw S.C., van den Berg H.M., Fischer K., et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood 2013, 121(20):4046-4055.
49. Kraft J., Blanchette V., Babyn P., et al. Magnetic resonance imaging and joint outcomes in boys with severe hemophilia A treated with tailored primary prophylaxis in Canada. J Thromb Haemost 2012, 10(12):2494-2502.
50. Van Den Berg H.M., Fischer K., Van Der Bom J.G. Comparing outcomes of different treatment regimens for severe haemophilia. Haemophilia 2003, 9:27-31.
51. Hacker M.R., Geraghty S., Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia 2001, 7(4):392-396.
52. Lindvall K., Colstrup L., Wollter I.M., et al. Compliance with treatment and understanding of own disease in patients with severe and moderate haemophilia. Haemophilia 2006, 12(1):47-51.
53. De Moerloose P., Urbancik W., Van Den Berg H.M., Richards M. A survey of adherence to haemophilia therapy in six European countries: results and recommendations. Haemophilia 2008, 14(5):931-938.
54. Duncan N., Shapiro A., Ye X., Epstein J., Luo M.P. Treatment patterns, health-related quality of life and adherence to prophylaxis among haemophilia A patients in the United States. Haemophilia 2012, 18(5):760-765.
55. Feldman B.M., Funk S.M., Bergstrom B.-M., et al. Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: Validity of the hemophilia joint health score. Arthritis Care Res 2011, 63(2):223-230.
56. Doria A.S., Keshava S.N., Mohanta A., et al. Diagnostic accuracy of ultrasound for assessment of hemophilic arthropathy: MRI correlation. Am J Roentgenol 2015, 204(3):W336-W347.
57. Lundin B., Manco-Johnson M.L., Ignas D.M., et al. An MRI scale for assessment of haemophilic arthropathy from the International Prophylaxis Study Group. Haemophilia 2012, 18(6):962-970.
58. Carcao M. Changing paradigm of prophylaxis with longer acting factor concentrates. Haemophilia 2014, 20:99-105.
59. Rath T., Baker K., Dumont J.A., et al. Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. Crit Rev Biotechnol 2013, 35(2):235-254.
60. Metzner H.J., Pipe S.W., Weimer T., Schulte S. Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin. Thromb Haemost 2013, 110(5):931-939.
61. Collins P.W., Bjorkman S., Fischer K., et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost 2010, 8(2):269-275.
62. Tang L., Wu R., Sun J., et al. Short-term low-dose secondary prophylaxis for severe/moderate haemophilia A children is beneficial to reduce bleed and improve daily activity, but there are obstacle in its execution: a multi-centre pilot study in China. Haemophilia 2013, 19(1):27-34.